Blood Clot Treatment Found By Researchers At Verseon Corporation

Verseon Corporation made a press release on Dec. 7, 2016, which states that they have successfully developed a new class of anticoagulant drugs for blood clot treatment. The press release emphasizes on the various research publications that support the efficacy of the new drug. Additionally, it also claims that the new range of anticoagulants can replace the NOACs for blood clot treatment methods.

According to Verseon, Dr. Mohan Sivaraja, Associate Director of Discovery Biology, Verseon Corporation, presented the primary research findings on the direct thrombin inhibitors (VE-DTIs), which are capable of blocking fibrinogen cleavage along with preserving platelet function. Platelets are highly important for wound healing, tissue growth and to stop bleeding at wounded sites, Blood reports. Due to the preservation of platelet function the bleeding risks associated with the administration of direct thrombin inhibitors (VE-DTIs) is extremely low.

The preclinical research findings on the new anticoagulants were presented at the ASH (American Society of Hematology) Annual Meeting, which was held on Dec. 5, 2016. The scientists from Verseon Corporation discussed the advantages and affectivity of the multiple novel anticoagulants developed by them. It was also pointed out that the new drugs are as effective as the NOACs in preventing thrombosis but with the additional advantage of reduced life-threatening bleeding risk associated with NOACs, according to PLOS ONE.

Dr. Mohan Sivaraja said that, "This unique feature of our novel class of thrombin inhibitors provides a biological explanation for their low bleeding liability," and he also stressed that "These encouraging results further establish the distinctive pharmacology of our compounds and could lead to improved blood thinners."

According to Verseon Corporation, its proprietary, computationally driven drug discovery platform will help in the development of new and advanced drugs for widespread pharmaceutical applications in the future. In addition to these new range of anticoagulants, Verseon is also working on development of novel drugs related to diabetic macular edema and oncology. These programs are in the preclinical testing phase and the corporation is highly optimistic about the results.